Novo Nordisk | NVO - Operating Profit


Novo Nordisk reported DKK5.18B in Operating Profit for its fiscal quarter ending in June of 2025.





Operating Profit Change Date
ANI Pharmaceuticals USD 38.71M 9.58M Mar/2026
Aurora Cannabis CAD -35.79M 19.88M Dec/2025
Bausch Health Companies USD 489M 230M Mar/2026
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Canopy Growth CAD -12.66M 1.64M Dec/2025
Corcept Therapeutics USD -49.6M 54.09M Mar/2026
Drreddys Laboratories INR 14.33B 2.51B Dec/2025
Eli Lilly USD 9.78B 792M Mar/2026
GlaxoSmithKline GBP 2.29B 856M Mar/2026
Merck USD -1.88B 8.12B Mar/2026
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
Novartis USD 4.24B 171M Mar/2026
Novo Nordisk DKK 59.62B 27.24B Mar/2026
Novo Nordisk DKK 5.18B 33.61B Jun/2025
Pacira USD 4.62M 1.43M Mar/2026
Perrigo USD 33.6M 50.8M Mar/2026
Phibro Animal Health USD 54.99M 2.36M Dec/2025
Prestige Brands USD 75.49M 7M Mar/2026
Sanofi EUR 1.94B 239M Mar/2026
Supernus Pharmaceuticals USD -35.25M 49.07M Mar/2026
Zoetis USD 865M 30M Mar/2026